BioNTech and Pfizer evaluate Omicron-speci...Pfizer Inc and BioNTech SE have started clinical safety testing of an Omikron-specific vaccine in healthy adults 18 through 55 years of age. more ➔
Cytovation AS kicks-off with $20m Series A...Norways immuno-oncology specialist Cytovation A/S has raised $20m in a Series A financing led by early-stage investor Sandwater. more ➔
Valneva vaccine neutralises Omicron varian...French-Austrian vaccine specialist Valneva SE has demonstrated that its COVID-19 vaccine induced neutralisation of 87% of the Omicron variant. more ➔
Neurimmune expands drug discovery collabor...Swiss Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. covering antibody drug targeting neurodegenerative diseases more ➔
Evotec and Lilly to collaborate in metabol...German Evotec SE has entered into a US$1bn drug discovery and development partnership with Eli Lilly and Company in the field of metabolic and renal diseases and diabetes. more ➔
Protagen, BioAnalytix and GeneWerk launch...Following their last year announcement to merge, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH launch a CRO named ProtaGene. more ➔
BioNTech SE licences Cresendo Bios Humab...BioNTech and Crescendo Biologics have signed a US-$790m deal to develop multi-specific precision immunotherapies . more ➔
Novartis AG executes licence option with M...After Molecular Partners AG reported an 78% reduction of hospitalisation by a single ensovibep dose in infected COVID-19 patients, Novartis AG is to pay a CHF150m milestone. more ➔
Neurimmune inks US-$760 deal with AstraZen...Neurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006. more ➔
Santhera finds Chinese marketing partner f...Swiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone. more ➔
